Tuesday Nov 3 | Medical News Today
BARACLUDE(R) (entecavir) Demonstrated Greater Antiviral Efficacy...
BARACLUDE Demonstrated Greater Antiviral Efficacy Compared To Adefovir In New Study Of Chronic Hepatitis B Patients With Cirrhosis Main Category: Liver Disease / Hepatitis Article Date: 03 Nov 2009 - 4:00 PST Bristol-Myers Squibb today announced 48-week data from an ongoing study of chronic hepatitis B patients with decompensated cirrhosis, in ...
Tenofovir (Viread) Suppresses HBV Viral Load Long-term in HIV/HBV...
Tenofovir Suppresses HBV Viral Load Long-term in HIV/HBV Coinfected Patients, but Kidney Function May Decline SUMMARY: HIV/HBV coinfected individuals treated with agents that are dually active against both virus experience rapid suppression of hepatitis B virus , and about 15% of those taking tenofovir plus emtricitabine achieve hepatitis B "e" ...
Most Patients with Low Baseline HBV Viral Load Can Safely Discontinue ...
Most Patients with Low Baseline HBV Viral Load Can Safely Discontinue Lamivudine after Achieving Virological Suppression Most chronic hepatitis B patients with low pre-treatment HBV DNA levels with pre-treatment HBV DNA < 10 8 copies/mL. This difference in cumulative relapse rates between the 2 groups was statistically significant .
Resistance to Hepatitis B Drugs is Common among HIV/HBV Coinfected...
The material posted on HIV and Hepatitis.com about the 49th ICAAC is not approved by the American Society for Microbiology Resistance to Hepatitis B Drugs is Common among HIV-HBV Coinfected Patients Receiving Lamivudine-containing ART without Tenofovir Resistance to the hepatitis B drugs adefovir , entecavir , and telbivudine is common among ...
Current management of Hep B before and after liver transplantation
The most recent issue of Liver Transplantation investigates current management of hepatitis B virus infection before and after liver transplantation.
HIV-HBV Coinfected Patients Respond to Antiretroviral Therapy as well ...
HIV positive people coinfected with hepatitis B virus respond as well to combination antiretroviral therapy as individuals with HIV alone, but they are more likely to die due to non-AIDS-related causes, according to a study published in the September 10, 2009 issue of AIDS .
Sustained Response in HBeAg Negative Chronic Hepatitis B Patients 3...
About one-quarter of hepatitis B "e" antigen negative patients treated with pegylated interferon alfa-2a for 48 weeks continued to demonstrate sustained biochemical and virological responses up to 3 years after completing therapy, according to a study in the June 2009 issue of Gastroenterology .
Triple drug treatment during pregnancy reduces risk of nevirapine resistance
A small Kenyan study has contributed new information to the complex body of evidence that is helping researchers identify new strategies for the prevention of mother-to-child transmission of HIV .
Systematic review: the effect of preventive lamivudine on hepatitis B ...
Abstract BACKGROUND: Lamivudine is increasingly being used to prevent hepatitis B reactivation in patients with cancer who test positive for hepatitis B surface antigen and are undergoing chemotherapy.
Systematic review: the effect of preventive lamivudine on hepatitis B ...
Abstract BACKGROUND: Lamivudine is increasingly being used to prevent hepatitis B reactivation in patients with cancer who test positive for hepatitis B surface antigen and are undergoing chemotherapy.
Predictors of Good Response to Telbivudine (Tyzeka) for Chronic Hepatitis B
Low baseline HBV viral load was the strongest overall predictor of favorable outcomes for patients treated with telbivudine in the GLOBE trial, with other predictive factors differing between hepatitis B "e" antigen positive and negative participants.
Perhaps More Lipodystrophy With Sustiva?
More Treatment News July 30, 2009 by David Evans People taking a regimen including Sustiva appeared to have greater limb fat loss and gut fat accumulation than those on Kaletra -based regimen, according to a study presented at the Fifth International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention in Cape Town.
Antiretroviral Regimens with Lamivudine (Epivir) Produce Good CD4...
The material posted on HIV and Hepatitis.com about IAS 2009 is not approved by nor is it a part of IAS 2009.
Pediatric Viramune May Still Work as Treatment in Kids Exposed at Birth
More Treatment News July 22, 2009 Pediatric Viramune May Still Work as Treatment in Kids Exposed at Birth by Tim Horn Infants exposed to single-dose Viramune monotherapy at the time of delivery - potentially resulting in rapid resistance to the drug if HIV infection does occur - may still benefit from a Viramune-based treatment regimen, according ...
Integrase Inhibitor Raltegravir (Isentress) Compares Favorably to...
The material posted on HIV and Hepatitis.com about IAS 2009 is not approved by nor is it a part of IAS 2009.
Lamivudine and Hepatitis B Reactivation
We thank Dr. Hsu and colleagues for their comments on our meta-analysis. We agree that corticosteroids play an important role in chemotherapy-induced HBV reactivation, which is why we listed corticosteroid use in a dedicated column in Table 1 of our article.
Interview: Understanding the fundamentals
Morris Robins talks to Kathleen Too about turning crystalline sugars black, discovering Epivir and Cladribine and his new career in farming Professor Morris J. Robins is a former professor at Brigham Young University, Utah, US.
Entecavir (Baraclude) Has Reduced Activity in Hepatitis B Patients...
Entecavir Has Reduced Activity in Hepatitis B Patients Failing Adefovir , but Resistance Is Rare in Treatment-naive People Chronic hepatitis B patients who still had detectable HBV viral load despite treatment with adefovir responded poorly to entecavir , indicating drug resistance.
Newer Anti-HIV Drugs and How to Use Them: Part I
There are currently several new anti-HIV drugs that have been approved by the U.S. Food and Drug Administration or that are in clinical testing.
HIV Coinfection Has Little Effect on Response to Chronic Hepatitis B Treatment
Studies have consistently shown that HIV-HCV coinfected patients do not respond as well to interferon-based therapy as those with HCV monoinfection .
Also on Topix